- RuxolitinibRuxolitinib (Opzelura™) is the only medication approved by the U.S. Food and Drug Administration (FDA) to restore lost skin color in people who have vitiligo. This JAK inhibitor is a cream that’s approved to treat people 12 years of age and older who have non-segmental vitiligo. It’s prescribed to treat a small area of the body.www.aad.org/public/diseases/a-z/vitiligo-treatment
- People also ask
Treatment for Nonsegmental Vitiligo | OPZELURA® (ruxolitinib)
WEBOPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older. The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong …
See results only from opzelura.comWhat is OPZELURA
What is OPZELURA - Treatment for Nonsegmental Vitiligo | OPZELURA® …
OPZELURA Results
OPZELURA Results - Treatment for Nonsegmental Vitiligo | OPZELURA® …
Safety & Side Effects
Two Years of Safety Data. At six months, the most common side effects (occurring …
Discussing OPZELURA
Discussing OPZELURA - Treatment for Nonsegmental Vitiligo | OPZELURA® …
Staying on Track
Staying on Track - Treatment for Nonsegmental Vitiligo | OPZELURA® …
Stay Informed
Stay Informed - Treatment for Nonsegmental Vitiligo | OPZELURA® …
Share Your Story
Share Your Story - Treatment for Nonsegmental Vitiligo | OPZELURA® …
Copay Savings Program
Copay Savings Program - Treatment for Nonsegmental Vitiligo | OPZELURA® …
What is Vitiligo? | OPZELURA® (ruxolitinib)
WEBOPZELURA is a prescription medicine used on the skin (topical) for the treatment of a type of vitiligo called nonsegmental vitiligo in adults and children 12 years of age and older. …
Nonsegmental Vitiligo Treatment | OPZELURA® …
WEBINDICATION. OPZELURA is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Limitations of Use: Use of OPZELURA in combination with …
Opzelura | European Medicines Agency
WEBFeb 24, 2023 · Opzelura is a medicine used for treating non-segmental vitiligo, a disease that causes patches of skin to lose colour on both sides of the body. In patients …
FDA approves topical treatment addressing repigmentation in …
- Safety and effectiveness of Opzelura were demonstrated in two clinical trials, NCT04052425 and NCT04057573. In both trials, subjects with nonsegmental vitiligo were randomized to treatment with Opzelura or placebo cream twice daily for 24 weeks, followed by an additional 28 weeks of treatment with Opzelura for all subjects. At the end of the 24-wee...
FDA Approves First Topical Treatment for Vitiligo
WEBJul 26, 2022 · Key Takeaways. Opzelura (ruxolitinib), the first topical cream to treat vitiligo, recently gained FDA approval. Based on data from the clinical trials, 30% of the participants regained at least 75% skin …
Opzelura ( ruxolitinib - European Medicines Agency
WEBOpzelura is a medicine used for treating non-segmental vitiligo, a disease that causes patches of skin to lose colour on both sides of the body. In patients with vitiligo, the …
FDA Approves Ruxolitinib (Opzelura) for Vitiligo - Everyday Health
WEBJul 22, 2022 · FDA Approves New Vitiligo Treatment, Ruxolitinib (Opzelura) The JAK inhibitor cream is the first medication that can restore pigment in people with this …
Facts About Vitiligo | OPZELURA® (ruxolitinib) HCP
WEBINDICATION. OPZELURA is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Limitations of Use: Use of …
Dosing | Nonsegmental Vitiligo | OPZELURA® (ruxolitinib) HCP
WEBINDICATION. OPZELURA is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Limitations of Use: Use of …
Skip to content
